x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Mendelspod Podcast

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who"s who in genomics and genomic medicine. www.mendelspod.com

science & medicine natural sciences

All Episodes

39:36

The Eligible But Under-Tested: Genomic Medicine in...

Mendelspod Podcast ·

2026/04/14

What is the value of someone’s genome over their life? Is a genome today what it was 10 years ago? How does the adoption of genomic testing compare to other areas in medicine, such as imaging or electronic health records?Today we take a pretty comprehensive look at genomic testing in practice with Damon Hostin, Head of Market Access, Clinical Solutions at Illumina. Damon brings a rare perspective to this conversation. He’s been in the field since the Celera era, when sequencing was helping define

en

31:43

Spatial Transcriptomics Is Changing How We Do...

Mendelspod Podcast ·

2026/04/09

Fei Chen of the Broad Institute describes the original problem simply: genomics gave us powerful inventories of gene expression, while microscopy gave us structure—yet the two lived in separate worlds. “You could either have your structure or you could have gene expression, but you couldn’t have both.”In this conversation, Fei walks us through how Slide-tags—now commercialized as Takara Bio Trekker technology—set out to close that gap. Instead of mapping gene expression onto a grid, his team flipped

en

44:06

Beyond GLP-1: Why Peptides Are Back at the Center of...

Mendelspod Podcast ·

2026/04/07

Peptides are having a moment. But beneath the market excitement and the GLP-1 headlines, something more interesting is going on. A field that for years seemed technically promising but perpetually constrained is becoming wide open.To see into that open terrain, we’re joined by Charlie Johannes, founder of EPOC Scientific and president of the Peptide Drug Hunting Consortium, along with Tomi Sawyer, a founder of the Consortium and founder of Maestro Therapeutics. We asked them for a high-level look at

en

35:51

From the Archives: Inventor Mark Kokoris Debuts...

Mendelspod Podcast ·

2026/04/02

It was the biggest story in sequencing last year: Mark Kokoris, head of SBX sequencing at Roche and inventor of the technology, joins Mendelspod to talk about how Sequencing by Expansion (SBX) works and why it may redefine the limits of genomics.* 0:00 A long journey inspired by PCR* 7:20 What is sequencing by expansion?* 14:00 On scale and accuracy* 19:40 Multi-omics vision?* 24:40 What will be the killer app?* 30:00 Biggest challenge for launchKokoris recounts the long path from co-founding

en

38:22

Why Do Some Animals Live Ten Times Longer? Pursuing...

Mendelspod Podcast ·

2026/03/17

Why do some animals live ten times longer than others?That question opens today’s interview with Steve Austad, Distinguished Professor at the University of Alabama at Birmingham and one of the leading thinkers in the biology of aging. It quickly becomes clear why he’s been such an important voice in bringing aging research from the margins into the center of science. As he puts it, the field was once “where scientists went to die,” but with modern genetic and molecular tools, it has become one of

en

33:33

MRD Testing: From Residual Disease to Real Decisions...

Mendelspod Podcast ·

2026/03/10

Molecular residual disease, or MRD, has been part of oncology’s vocabulary for decades. But knowing something is there and being able to measure it precisely are two very different things. In today’s show, we explore how MRD testing moved from a long-standing clinical suspicion to one of the most consequential tools in modern oncology.Joining us on the program are Chris Hourigan, Director of the Fralin Biomedical Research Institute Cancer Research Center (DC) at Virginia Tech, bringing the

en

4:06

Early vs Late Recurrence: How Multimodal AI Is...

Mendelspod Podcast ·

2026/03/05

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comFor two decades, tests like Oncotype DX have helped oncologists decide which early-stage breast cancer patients should receive chemotherapy. But those tools were designed mainly to predict early recurrence, leaving physicians with far less clarity about the risk that cancer might return years later.For today’s program, George Sledge, Chief Medical Officer at Caris Life Sciences, discusses new findings from the TAILORx

en

37:17

The Dark Genome with Author Sudhakaran Prabakaran

Mendelspod Podcast ·

2026/03/03

We began this podcast back around the time the ENCODE project announced that much of the genome was biochemically active. The big science project was undoing the tidy idea of “junk DNA,” and not without controversy. But activity is not the same as purpose. On today’s show, we move past the question of whether the non-coding genome does something and ask a more ambitious one: why has evolution retained so much genomic material unless it carries adaptive potential?Theral speaks with Sudhakaran

en

27:15

Illumina's New Mapped Read Technology Provides...

Mendelspod Podcast ·

2026/02/26

“We have been talking now for 15, 20 years about the diagnostic odyssey. That shouldn’t exist anymore. The new odyssey is the therapeutic odyssey.”That’s Stephen Kingsmore, president and CEO of Rady Children’s Hospital (he just announced his retirement), explaining the impact of a new genome mapping technology from Illumina.Whole-genome sequencing has transformed diagnosis, but some of the hardest pediatric cases persist because the structure of the genome has remained difficult to resolve. Today on

en

5:28

CareDx’s Second Act with CEO John Hanna

Mendelspod Podcast ·

2026/02/17

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comCareDx is a company on the move. For years, they have been a bellwether in molecular diagnostics. Their early bet on gene expression testing in transplant medicine, their bruising fight over Medicare coverage, and their pivot into cell-free DNA monitoring have all reflected the growing pains of precision medicine itself.Now, under CEO John Hanna, the company looks less like a single-test diagnostics firm and more like a

en

40:44

Inside GP2: Building a Global Genetic Map of...

Mendelspod Podcast ·

2026/02/10

Large-scale genomics is back — and this time, it’s global by design.In this episode of Mendelspod, we return to the kind of ambitious, shared genomics project that helped define the field a decade ago. The Global Parkinson’s Genetics Program (GP2) has now genotyped more than 100,000 participants worldwide, with roughly one third of samples coming from historically underrepresented populations. That scale and diversity are already reshaping how Parkinson’s disease is studied — and how it may

en

30:40

A Simple Sponge, a Big Shift in Cell Therapy with Yev...

Mendelspod Podcast ·

2026/02/03

What if the hardest part of scaling cell therapy turned out to be a materials problem not a biological one—and the solution looked like a sponge?On today’s show, Theral speaks with Yev Brudno, Associate Professor in the School of Pharmacy and also the Department of Biomedical Engineering at the University of North Carolina at Chapel Hill, about a deceptively simple technology that could dramatically accelerate manufacturing and lower the cost of cell therapies. Brudno’s lab works at the intersection

en

23:57

How Cellanome Is Changing the Way We Study Cell...

Mendelspod Podcast ·

2026/01/29

For today’s show, we return to discussing the exciting new Cellanome platform. Joining Theral are Pier Federico Gherardini, VP of Computational Biology at Cellanome, and Matthew Spitzer, Associate Professor at University of California, San Francisco, whose lab is using Cellanome’s CellCage technology to study immune cells in dynamic, interactive contexts.0:00 From static snapshots to observing cell function in real time4:45 Pairing phenotype with function like we never could before7:30 Can see

en

41:59

From Hereditary Risk to Residual Disease: Natera’s...

Mendelspod Podcast ·

2026/01/28

Half of oncologists in the U.S. are now ordering MRD testing, according to Adam ElNaggar, MD of Natera — but the other half, he says, “are still figuring out how to use it, or that it even exists.”In this episode, we talk with ElNaggar about the rapid rise of ctDNA-based monitoring and how it’s changing the very rhythm of cancer care. From Natera’s “tumor-informed” SignateraTM assay to its new “tissue-free” LatitudeTM test, the company is reshaping oncology around the molecular traces that cancer

en

46:16

The Rise of Geroscience with Alan Landay and Tom...

Mendelspod Podcast ·

2026/01/22

Aging may be the last great frontier of precision medicine—not a single disease, but the slow re-patterning of immunity, metabolism, and resilience that determines how well and how long we live.In this wide-ranging and genuinely mind-bending conversation, Alan Landay and Tom Blackwell make a compelling case that aging itself is finally becoming a legitimate—and testable—target of medicine.For Landay, the path into aging biology began decades ago through HIV. Antiretroviral therapy transformed HIV

en

4:43

Unlocking the RNA Revolution: How Self-Replicating...

Mendelspod Podcast ·

2026/01/15

This is a free preview of a paid episode. To hear more, visit www.mendelspod.comThe RNA revolution didn’t end with COVID. It’s only just beginning.Today Theral is joined by Andrew Geall, co-founder and Chief Development Officer of Replicate Bioscience, to explore why self-replicating RNA may represent the next major leap in vaccines and therapeutics. While first-generation mRNA proved what was possible in a pandemic, Andrew argues …

en

34:11

From Targets to Hits: The Emerging AI Ecosystem in...

Mendelspod Podcast ·

2026/01/09

Perhaps more than in any other field, AI is impacting drug discovery and development. To begin the year we’re joined by two AI software-as-service companies, one on the target discovery side and the other built for new compound identification for those targets.Theral speaks with Aqib Hasnain, Product Lead at Mithrl, and Cheng Hu, co-founder and CEO of Technetium Therapeutics, about how scientists can go from AI generated insights to AI generated assets, from AI-driven fast science, to AI-driven fast

en

38:30

Most Popular Show of 2025: How Certis Is Rewriting...

Mendelspod Podcast ·

2025/12/30

In our most listened to episode this year, Certis Oncology CEO Peter Ellman breaks down how his company is reinventing cancer research by building orthotopic patient-derived tumor models that more faithfully mimic human cancer — and using them to improve both drug development and treatment decisions. What is meant by orthotopic? That’s when patient tumors are placed in the “correct place” inside mice to create more faithful cancer models.Ellman shares the deeply personal origin story behind

en

26:49

Building the Front-End for Every Sequencer with Volta...

Mendelspod Podcast ·

2025/12/18

As sequencing continues to become cheaper, more attention is being paid to sample prep. Today we’re following up with the company, Volta Labs, a genomics applications company transforming sample prep for NGS by increasing robustness and precision, and lowering operating costs. CEO Udayan Umapathi reflects on what has been a breakout first commercial year for Callisto, the company’s sequencer-agnostic, digital-fluidics platform for sample prep. When he was last on the show, Callisto had just

en

42:07

A New Foundational Platform for Biology: Cellanome’s...

Mendelspod Podcast ·

2025/12/17

Few startups have launched with such quiet anticipation—or such a remarkable founding pedigree—as Cellanome. Backed by veterans of the genomics revolution, the company aims to do for cell biology what Illumina did for sequencing: make it measurable, dynamic, and multidimensional.In this debut conversation, Cellanome CEO Omead Ostadan traces his path from the early days of Applied Biosystems and Solexa to what he calls “the multi-omics of the cell.” He describes a breakthrough platform capable of

en

543 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事